Published in J Immunol on September 04, 2009
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A (2010) 1.37
Synthesis of immunostimulatory alpha-C-galactosylceramide glycolipids via Sonogashira coupling, asymmetric epoxidation, and trichloroacetimidate-mediated epoxide opening. Org Lett (2010) 0.95
Α-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents. PLoS One (2010) 0.93
A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity. Semin Immunol (2009) 0.86
Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. PLoS One (2014) 0.82
CD1d protein structure determines species-selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant NKT cells. Eur J Immunol (2013) 0.81
Functional invariant NKT cells in pig lungs regulate the airway hyperreactivity: a potential animal model. J Clin Immunol (2010) 0.81
Invariant natural killer T cells in rheumatic disease: a joint dilemma. Nat Rev Rheumatol (2010) 0.78
C-Galactosylceramide: Synthesis and Immunology. C R Chim (2012) 0.78
Lipid and Carbohydrate Modifications of α-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation. J Biol Chem (2015) 0.77
CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science (1997) 13.67
Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol (2005) 7.08
Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 6.38
CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature (2007) 5.31
Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest (2004) 5.16
A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature (2001) 5.08
The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol (2005) 3.53
Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol (2005) 3.12
Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity (2009) 2.61
A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol Methods (2006) 2.36
Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc (2004) 2.05
Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat Protoc (2008) 1.94
Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J Immunol (2004) 1.73
The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc Natl Acad Sci U S A (2004) 1.61
Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J Biol Chem (2003) 1.61
A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. J Exp Med (2008) 1.60
Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc (2006) 1.47
Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell Mol Life Sci (2006) 1.27
Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol (2008) 1.17
Tissue distribution, regulation and intracellular localization of murine CD1 molecules. Mol Immunol (1998) 1.14
Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology (2009) 1.12
CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood (2007) 1.09
CD1d antigen presentation: treats for NKT cells. Nat Immunol (2005) 1.05
E and Z alpha-C-galactosylceramides by Julia-Lythgoe-Kocienski chemistry: a test of the receptor-binding model for glycolipid immunostimulants. Chembiochem (2006) 1.04
Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J Am Chem Soc (2008) 1.01
Modulation of CD1d-restricted NKT cell responses by CD4. J Leukoc Biol (2007) 1.00
Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. J Immunol Methods (2007) 0.90
Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 6.38
Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol (2006) 5.51
Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 3.48
A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med (2011) 2.78
Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med (2003) 2.64
Laparoscopic versus open colorectal surgery: a randomized trial on short-term outcome. Ann Surg (2002) 2.50
Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med (2002) 2.38
High-frequency and adaptive-like dynamics of human CD1 self-reactive T cells. Eur J Immunol (2011) 2.27
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci U S A (2005) 2.13
CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med (2003) 2.01
Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol (2009) 1.81
Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med (2002) 1.80
Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A (2006) 1.74
Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest (2010) 1.60
Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc (2006) 1.47
Cutting edge: influence of the TCR Vbeta domain on the selection of semi-invariant NKT cells by endogenous ligands. J Immunol (2006) 1.43
Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO J (2011) 1.43
Dicer-dependent microRNA pathway controls invariant NKT cell development. J Immunol (2009) 1.41
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A (2010) 1.37
Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol (2008) 1.32
The C-glycoside analogue of the immunostimulant alpha-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. Angew Chem Int Ed Engl (2004) 1.31
Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci U S A (2005) 1.29
NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood (2008) 1.28
Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J Immunol (2008) 1.26
Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol (2003) 1.25
Use of MHC class II tetramers to investigate CD4+ T cell responses: problems and solutions. Cytometry A (2008) 1.24
Follicular helper NKT cells induce limited B cell responses and germinal center formation in the absence of CD4(+) T cell help. J Immunol (2012) 1.22
Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine (2008) 1.19
Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res (2007) 1.19
Efficient synthesis of alpha-C-galactosyl ceramide immunostimulants: use of ethylene-promoted olefin cross-metathesis. Org Lett (2004) 1.19
Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J Immunol (2008) 1.18
Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA. J Infect Dis (2008) 1.16
T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol (2002) 1.14
Lipid-protein interactions: biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved. Proc Natl Acad Sci U S A (2004) 1.13
Characterization of histopathology and gene-expression profiles of synovitis in early rheumatoid arthritis using targeted biopsy specimens. Arthritis Res Ther (2005) 1.13
Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol (2004) 1.12
Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology (2009) 1.12
Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest (2010) 1.12
Targeted expression of human CD1d in transgenic mice reveals independent roles for thymocytes and thymic APCs in positive and negative selection of Valpha14i NKT cells. J Immunol (2005) 1.11
CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood (2007) 1.09
Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development. J Exp Med (2008) 1.08
Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res (2012) 1.08
Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J Immunol (2004) 1.07
Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J Immunol Methods (2009) 1.07
Endothelin in a murine model of cerebral malaria. Exp Biol Med (Maywood) (2006) 1.06
The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med (2009) 1.06
Alpha-c-galactosylceramides: synthesis and immunology. Acc Chem Res (2006) 1.05
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine (2009) 1.05
Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice. J Immunol (2003) 1.04
E and Z alpha-C-galactosylceramides by Julia-Lythgoe-Kocienski chemistry: a test of the receptor-binding model for glycolipid immunostimulants. Chembiochem (2006) 1.04
Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection. Int Immunol (2007) 1.03
Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine (2004) 1.02
Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J Am Chem Soc (2008) 1.01
Loss of T cell microRNA provides systemic protection against autoimmune pathology in mice. J Autoimmun (2012) 1.00
NKT TCR recognition of CD1d-α-C-galactosylceramide. J Immunol (2011) 0.99
The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res (2003) 0.99
Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect Immun (2013) 0.99
Fine tuning by human CD1e of lipid-specific immune responses. Proc Natl Acad Sci U S A (2011) 0.98
A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J Immunol (2007) 0.97
Reduced cerebral blood flow and N-acetyl aspartate in a murine model of cerebral malaria. Parasitol Res (2005) 0.97
Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood (2006) 0.97
Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol (2010) 0.96
The dendritic cell-specific chemokine, dendritic cell-derived CC chemokine 1, enhances protective cell-mediated immunity to murine malaria. J Immunol (2003) 0.96
Carbohydrates and T cells: a sweet twosome. Semin Immunol (2013) 0.95
Intracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation. PLoS One (2013) 0.94